FDA approves Teva's digital inhaler for asthma and COPD patients

Teva Pharmaceutical Industries' ProAir inhaler has been approved by FDA for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm in patients aged 4 years and older.

Teva Pharmaceutical Industries' ProAir inhaler has been approved by FDA for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm in patients aged 4 years and older. The company describes the device as "the first and only digital inhaler with built-in sensors that detect when the inhaler is used and measure inhalation flow." The inhaler is linked to a companion mobile application that provides inhaler-use data to people with asthma and COPD via Bluetooth technology so patients can review their data over time and share it with health care professionals. Tonya Winders, president and CEO of the Allergy & Asthma Network, observes: "[The FDA approval of Teva's device] may help patients track their inhaler usage and provide data that can be used to work more closely with their health care providers on their asthma management." Teva says its ProAir Digihaler will be available in 2019 through a small number of "early experience" programs, which will be launched in conjunction with health care systems and in limited areas "in order to gather real-world experience." Nationwide distribution of the device is planned for 2020.